Clinical Trial Update: Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in breast cancer compares TAC chemotherapy with or without bevacizumab; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED